Varvat Jérôme, Epinat Magali, Nuti Christophe, Antoine Jean-Christophe, Mismetti Patrick, Garnier Pierre
Unité Neurovasculaire, CHU, Saint-Étienne, France.
Therapie. 2013 May-Jun;68(3):143-7. doi: 10.2515/therapie/2013029. Epub 2013 Jul 26.
Intracranial hemorrhage (ICH) is an antithrombotic treatment complication. Our study's goal is to assess the proportion of ICH occurring while the patient is on antithrombotic treatment. The secondary goal is to assess the proportion of "avoidable" ICH (anticoagulant overdosage, debatables indications).
We conducted a descriptive epidemiological single-center study of ICH during 2 years. We analyzed the type of ICH, the type of antithrombotic treatment, the level of anticoagulation and the relevance of antithrombotic treatment indication.
Of the 400 patients admitted for an ICH, 131 (33%) were treated by antithrombotic therapy: oral anti-vitamin K anticoagulants (VKA) in 14.1% of cases and antiplatelet agents in 15.1%. Of VKA patients, overdosage rate was 30.2%. The indication of antithrombotic therapy was debatable in 18.3% of cases.
Our study highlights the frequency of ICH occurring on antithrombotic therapy and the significant proportion of "avoidable" ICH.
颅内出血（ICH）是抗血栓治疗的一种并发症。我们研究的目的是评估患者在接受抗血栓治疗期间发生ICH的比例。次要目的是评估“可避免的”ICH（抗凝药物过量、有争议的适应证）的比例。
我们对两年内的ICH进行了一项描述性流行病学单中心研究。我们分析了ICH的类型、抗血栓治疗的类型、抗凝水平以及抗血栓治疗适应证的相关性。
在400例因ICH入院的患者中，131例（33%）接受了抗血栓治疗：14.1%的病例使用口服维生素K拮抗剂（VKA），15.1%的病例使用抗血小板药物。在使用VKA的患者中，过量率为30.2%。18.3%的病例中抗血栓治疗的适应证存在争议。
我们的研究突出了抗血栓治疗期间发生ICH的频率以及“可避免的”ICH的显著比例。
